Role of PET/PET-CT in the management of sarcomas.

abstract：INTRODUCTION:In breast cancer, estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: tempora...

journal_title：Expert review of anticancer therapy

authors： Martínez-Pérez C,Turnbull AK,Dixon JM

更新日期：2019-02-01 00:00:00

abstract：:Atypical hyperplasia and lobular carcinoma in situ are rare proliferative breast lesions, growing inside ducts and terminal ducto-lobular units. They represent a marker of increased risk for breast cancer and a non-obligate precursor of malignancy. Evidence available on diagnosis and management is scarce. They are fre...

journal_title：Expert review of anticancer therapy

authors： Clauser P,Marino MA,Baltzer PA,Bazzocchi M,Zuiani C

更新日期：2016-01-01 00:00:00

abstract：:Hematopoietic stem cell transplantation is an effective treatment for patients with relapsed or refractory Hodgkin lymphoma. Treatment outcome is better among patients who demonstrate sensitivity to salvage chemotherapy. Approximately half of the patients undergoing autologous stem cell transplantation will be cured a...

journal_title：Expert review of anticancer therapy

authors： Murphy F,Sirohi B,Cunningham D

更新日期：2007-03-01 00:00:00

abstract：:With the association of concurrent chemotherapy, the widespread implementation of altered fractionation schedules and the use of more conformal radiotherapy techniques, the locoregional management of patients with squamous cell carcinoma of the head and neck region (HNSCC) has greatly improved over the last decades. H...

journal_title：Expert review of anticancer therapy

authors： Lambrecht M,Dirix P,Vandecaveye V,De Keyzer F,Hermans R,Nuyts S

更新日期：2010-09-01 00:00:00

abstract：INTRODUCTION:A systematic review was performed to explore the health-related quality of life (HRQoL) outcomes among cancer patients receiving PD-(L)1 inhibitors compared to those receiving traditional cytotoxic therapy. Areas covered: Citations from PubMed and the American Society of Clinical Oncology meeting library w...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O,Oweira H,Giryes A

更新日期：2018-12-01 00:00:00

abstract：:Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarker...

journal_title：Expert review of anticancer therapy

authors： Reed AB,Parekh DJ

更新日期：2010-01-01 00:00:00

abstract：:The European Society for Medical Oncology (ESMO) recommendations on the management of gastrointestinal stromal tumor (GIST) have recently been updated. Imatinib 400 mg/day remains the standard first-line treatment for patients with metastatic GIST. Mutational analysis has received a strong recommendation for diagnosti...

journal_title：Expert review of anticancer therapy

authors： Blay JY,Reichardt P

更新日期：2009-06-01 00:00:00

abstract：:As diagnostic and therapeutic options increase, strategies for the treatment of non-small-cell lung cancer (NSCLC) are becoming more tailored for specific patient subpopulations and individual patients. The introduction of therapy targeted against the EGF receptor (EGFR) pathway has provided new treatment options for ...

journal_title：Expert review of anticancer therapy

authors： Batus M,Fidler MJ,Bonomi PD

更新日期：2010-10-01 00:00:00

abstract：INTRODUCTION:Angiogenesis is a complex process regulated by several pro- and anti-angiogenic factors, thus the loss of its fine equilibrium plays a key role in colorectal cancer (CRC) development and progression. Therapeutic agents targeting VEGF/VEGFR signaling, the main regulator of this process, proved to be effecti...

journal_title：Expert review of anticancer therapy

authors： Battaglin F,Puccini A,Intini R,Schirripa M,Ferro A,Bergamo F,Lonardi S,Zagonel V,Lenz HJ,Loupakis F

更新日期：2018-03-01 00:00:00

abstract：:Small cell carcinoma of the urinary bladder (SCCUB) is a rare and aggressive disease. To date, no standard treatment has been proposed due to the lack of prospective studies resulting from the rarity of this disease. Recently published studies of relatively large patient cohorts, however, have shed some light on the m...

journal_title：Expert review of anticancer therapy

authors： Koga F,Yokoyama M,Fukushima H

更新日期：2013-11-01 00:00:00

abstract：:Limb-salvage surgery plays a major role in the management of patients with osteosarcoma. As prognosis improves, reconstructive options have come under greater scrutiny with regard to their durability and functionality. The advent of computer navigation-guided reconstruction is discussed in detail, along with methods b...

journal_title：Expert review of anticancer therapy

authors： Mangat KS,Jeys LM,Carter SR

更新日期：2011-02-01 00:00:00

abstract：:Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever pos...

journal_title：Expert review of anticancer therapy

authors： Vijayamurugan N,Bakhshi S

更新日期：2014-02-01 00:00:00

abstract：:Knowledge of the prognostic role of biomarkers in colorectal cancer is limited and the routine determination for clinical practice is not warranted. However, for some of these markers, data are promising enough for further evaluation. This review addresses a comprehensive analysis of prognostic biomarkers in colorecta...

journal_title：Expert review of anticancer therapy

authors： Graziano F,Catalano V,Baldelli AM,Cascinu S

更新日期：2001-08-01 00:00:00

abstract：INTRODUCTION:Endometrial cancer is a common gynecologic malignancy in the United States, and the recurrence rate depends on the disease stage at diagnosis. Recurrence can affect several areas and follow different patterns. AREAS COVERED:The role of surgery at the time of recurrence is not clearly defined. In this revi...

journal_title：Expert review of anticancer therapy

authors： Zanfagnin V,Ferrero A,Biglia N,Aletti G,Gill SE,Makdisi PB,Multinu F,Mariani A

更新日期：2016-07-01 00:00:00

abstract：:This article reviews the current status of robotic-assisted radical prostatectomy (RARP) with outcome analysis. The published English literature (PubMed) database was searched extensively for major publications and large series on RARP. The search was carried out over the preceding 3-year period. Selected series were ...

journal_title：Expert review of anticancer therapy

authors： Singh I,Hemal AK

更新日期：2010-05-01 00:00:00

abstract：:Advanced gastric cancer (GC) is a dreadful disease with a poor prognosis and the majority of patients die within 1 year of diagnosis. In the past decade, important signaling pathways promoting tumor proliferation and aggressiveness have been evaluated; the hepatocyte growth factor/mesenchymal epithelial transition (ME...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O

更新日期：2015-02-01 00:00:00

abstract：INTRODUCTION:Germ cell tumors (GCTs) are the most common solid malignancies in young men. The overall cure rate of GCT patients in metastatic stage is excellent, however; patients with relapsed or refractory disease have poor prognosis. Attempts to treat refractory disease with novel effective treatment to improve prog...

journal_title：Expert review of anticancer therapy

authors： Kozakova K,Mego M,Cheng L,Chovanec M

更新日期：2020-11-02 00:00:00

abstract：:Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary or acquired resistance to these agents remain...

journal_title：Expert review of anticancer therapy

authors： Metro G,Crinò L

更新日期：2011-05-01 00:00:00

abstract：:A lymphocele is a cystic mass that may occur in the retroperitoneum following a systematic pelvic and/or para-aortic lymphadenectomy. Lymphoceles may be the cause of severe morbidity, or rarely mortality. Symptomatic lymphoceles manifest with pain, compression of adjacent structures, lymphoedema, deep vein thrombosis ...

journal_title：Expert review of anticancer therapy

authors： Weinberger V,Cibula D,Zikan M

更新日期：2014-03-01 00:00:00

abstract：:The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30 years since the advent of combination chemotherapy with cytarabine arabinoside and daunorubicin with remission rates around 70% but with long term survival still only around 40% in young adults. Doses of chemotherapy have been push...

journal_title：Expert review of anticancer therapy

authors： Kell J

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Intrahepatic cholangiocarcinoma (ICC) is a highly malignant neoplasm. The incidence of ICC has been increasing world-wide over the past several decades. Areas covered: The pathogenesis of ICC is a complex process involving the alteration of specific genes and epigenetic changes. This review summarizes the ...

journal_title：Expert review of anticancer therapy

authors： Huang SB,Zheng CX

更新日期：2017-01-01 00:00:00

abstract：:The retinoblastoma (RB)-Cyclin (CCN)D1-p16 cell cycle pathway has a crucial role in lung tumorigenesis. Impairment of the RB pathway has been shown to occur in almost all lung tumors. A deregulation at any level of this core RB pathway seems to make cells insensitive to the mitogenic signaling that is required for cel...

journal_title：Expert review of anticancer therapy

authors： Wikman H,Kettunen E

更新日期：2006-04-01 00:00:00

abstract：:Introduction: Radiotherapy is an important therapeutic strategy in the management of non-small cell lung cancer (NSCLC). In recent decades, technological implementations and the introduction of image guided radiotherapy (IGRT) have significantly increased the accuracy and tolerability of radiation therapy.Area covered...

journal_title：Expert review of anticancer therapy

authors： Giaj-Levra N,Borghetti P,Bruni A,Ciammella P,Cuccia F,Fozza A,Franceschini D,Scotti V,Vagge S,Alongi F

更新日期：2020-05-01 00:00:00

abstract：:Raloxifene is a member of a family of drugs known as selective estrogen receptor modulators (SERMs). Raloxifene is currently approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women. SERMs hold the potential to treat and prevent breast cancer, osteoporosis and coronary heart disease...

journal_title：Expert review of anticancer therapy

authors： Pappas SG,Jordan VC

更新日期：2001-10-01 00:00:00

abstract：:Ovarian cancer is the leading cause of gynecologic cancer-related death in Europe and the USA. The optimal treatment strategy for this malignancy includes accurate presurgical and surgical staging, optimal debulking surgery, and first-line therapy with platinum-based chemotherapy. Unfortunately, the majority of patien...

journal_title：Expert review of anticancer therapy

authors： Guarneri V,Barbieri E,Dieci MV,Piacentini F,Conte P

更新日期：2011-01-01 00:00:00

abstract：:The prospects for the treatment of metastatic melanoma are improving. Whereas previous scientific meetings dedicated to the treatment of metastatic melanoma patients were overshadowed by our inability to improve overall survival or lengthen the time to progression, the results presented at the most recent meetings are...

journal_title：Expert review of anticancer therapy

authors： van Kempen LC

更新日期：2011-06-01 00:00:00

abstract：INTRODUCTION:Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immun...

journal_title：Expert review of anticancer therapy

authors： Kamath SD,Kalyan A,Benson AB 3rd

更新日期：2018-12-01 00:00:00

abstract：:Pulmonary complications of antineoplastic therapy are common and are an important cause of respiratory morbidity. The pulmonary toxicity should be taken into account in every patient with respiratory problems who is or has been treated with antineoplastic agents. The diagnosis of drug-induced pulmonary toxicity is com...

journal_title：Expert review of anticancer therapy

authors： Sadowska AM,Specenier P,Germonpre P,Peeters M

更新日期：2013-08-01 00:00:00

abstract：:Malignant gliomas are the most prevalent type of primary brain tumor in adults. Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. The median survival of patients with glioblastoma multiforme, the most common grade of malignant glioma, is 10-12 months. Conventional ther...

journal_title：Expert review of anticancer therapy

authors： Sathornsumetee S,Rich JN

更新日期：2006-07-01 00:00:00

abstract：:The monoclonal antibody against HER2, trastuzumab (Herceptin), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and surviva...

journal_title：Expert review of anticancer therapy

authors： Perik PJ,de Korte MA,van Veldhuisen DJ,Gietema JA,Sleijfer DT,de Vries EG

更新日期：2007-12-01 00:00:00